United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News How elraglusib’s long-term Phase 2 survival data positions Actuate Therapeutics in a difficult pancreatic cancer market Find out how elraglusib’s long-term Phase 2 survival data is positioning Actuate Therapeutics in the challenging metastatic pancreatic cancer market. bySoujanya RaviJanuary 15, 2026